← Back to Clinical Trials
Recruiting NCT07243639

NCT07243639 Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07243639
Status Recruiting
Phase
Sponsor Showa Inan General Hospital
Condition Ulcerative Colitis (Disorder)
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-10-01
Primary Completion 2027-09-30

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Etrasimod administration

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-10-01 with a primary completion date of 2027-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.

Eligibility Criteria

Inclusion Criteria: * Patients with active ulcerative colitis Exclusion Criteria: * the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease

Contact & Investigator

Central Contact

Norio Saegusa

✉ ikyoku.tosho@sihp.jp

📞 81265822121

Frequently Asked Questions

Who can join the NCT07243639 clinical trial?

This trial is open to participants of all sexes, studying Ulcerative Colitis (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07243639 currently recruiting?

Yes, NCT07243639 is actively recruiting participants. Contact the research team at ikyoku.tosho@sihp.jp for enrollment information.

Where is the NCT07243639 trial being conducted?

This trial is being conducted at Komagane, Japan.

Who is sponsoring the NCT07243639 clinical trial?

NCT07243639 is sponsored by Showa Inan General Hospital. The trial plans to enroll 30 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology